Lorbas - Market giving 100-200% with much less than such a important results as those today , after positive results with Maraviroc in colon cancer already.
The warrant holders are the problems imo , in one way they do help company in financing , in another hand they damaging pps.

With approval , FDA is very good , fast approval for deadly cancers , especially with medicine without serious side effects...

They probably will start with few patients and BTD , enrollment should be good now because of approval of IRB , this is an easy enrollment , no restrictions ...
And if good results , approval next year , 1H not excluded ..

I am going out now so have a good evening...



All IMO...